Back to top
more

GSK PLC Sponsored ADR (GSK)

(Real Time Quote from BATS)

$38.48 USD

38.48
801,093

-0.48 (-1.23%)

Updated Oct 18, 2024 11:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AstraZeneca (AZN) Antibody Cocktail Fails to Prevent COVID-19

by Zacks Equity Research

AstraZeneca's (AZN) antibody cocktail, AZD7442 fails to prevent people who were already infected from developing symptomatic COVID-19. However, it showed some efficacy in people who were not infected.

Glaxo (GSK)/iTeos Therapeutics to Co-Develop Novel Cancer Drug

by Zacks Equity Research

Glaxo (GSK) signs deal with iTeos Therapeutics to co-develop its investigational cancer candidate known as EOS-448. Glaxo will also study EOS-448 with its other investigational cancer therapies.

Gilead (GILD) Gets FDA Nod for Label Expansion of Epclusa

by Zacks Equity Research

Gilead (GILD) obtains FDA approval for the label expansion of HCV drug, Epclusa, to include children as well.

VBI Vaccines (VBIV) Up on Glioblastoma Drug Fast Track Status

by Zacks Equity Research

VBI Vaccines (VBIV) is developing VBI-1901 as a potential treatment of recurrent glioblastoma patients.

Sanofi (SNY) Stops Venglustat Development as Kidney Cyst Drug

by Zacks Equity Research

Sanofi (SNY) discontinues development of pipeline candidate, venglustat, in patients with autosomal dominant polycystic kidney disease, following failure in a pivotal study.

CureVac (CVAC) Announces Positive Data on COVID-19 Vaccine

by Zacks Equity Research

CureVac (CVAC) announces the continuation of its COVID-19 vaccine study following the first interim analysis in 59 eligible COVID-19 cases.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ Cancer Drug Gets FDA Nod, PFE, GSK, SNY Begin New Studies

by Kinjel Shah

Sanofi (SNY) and Glaxo's (GSK) COVID-19 vaccine candidate enters phase III. FDA approves J&J's (JNJ) Rybrevant (amivantamab) for a rare lung cancer

Sanofi/Glaxo Initiate Pivotal Global COVID-19 Vaccine Study

by Zacks Equity Research

Sanofi (SNY) and Glaxo initiate phase III study to evaluate their adjuvanted COVID-19 vaccine candidate. A booster program will start soon.

Vir Biotech (VIR)/Glaxo COVID-19 Drug Gets FDA Emergency Nod

by Zacks Equity Research

Glaxo (GSK)/VIR Biotech's (VIR) sotrovimab demonstrated an 85% reduction in hospitalization or death in a study evaluating it in high-risk COVID-19 patients.

Merck (MRK) Gets CHMP Nod for Keytruda in Esophageal Cancer

by Zacks Equity Research

The CHMP recommends approval of Merck's (MRK) anti-PD-1 therapy, Keytruda in combination with chemotherapy for the first-line treatment of esophageal and gastroesophageal junction carcinoma in Europe.

Glaxo (GSK)/ Vir Biotech's COVID-19 Antibody Gets CHMP Nod

by Zacks Equity Research

The CHMP issues a positive scientific opinion on Glaxo (GSK) and partner Vir Biotech's antibody candidate, sotrovimab (VIR-7831), for the treatment of adults and adolescents with COVID-19 infection.

The Zacks Analyst Blog Highlights: Sanofi, GlaxoSmithKline, Pfizer, Eli Lilly and Merck

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Sanofi, GlaxoSmithKline, Pfizer, Eli Lilly and Merck

Merck's (MRK) Pneumococcal Vaccine Succeeds in Pediatric Trials

by Zacks Equity Research

Merck's (MRK) 15-valent pneumococcal conjugate vaccine candidate, V114, demonstrates comparable immunogenicity and safety compared to a lower valency vaccine in infants and children.

Kinjel Shah headshot

Pharma Stock Roundup: GSK/SNY COVID-19 Vaccine Data, PFE's New EU Supply Deal

by Kinjel Shah

Sanofi (SNY) and Glaxo's (GSK) COVID-19 vaccine shows strong antibody response in phase II. Lilly's fifth phase III study on tirzepatide meets all key endpoints

The Zacks Analyst Blog Highlights: GlaxoSmithKline, Sanofi, CureVac and Vir Biotechnology

by Zacks Equity Research

The Zacks Analyst Blog Highlights: GlaxoSmithKline, Sanofi, CureVac and Vir Biotechnology

Sanofi (SNY) to Start Phase III COVID-19 Vaccine Study Soon

by Zacks Equity Research

Based on promising interim data from a phase II study, Sanofi (SNY) plans to initiate a pivotal late-stage study on its adjuvanted vaccine candidate being developed in collaboration with Glaxo in the coming weeks.

Glaxo/Medicago COVID-19 Vaccine Shows Strong Immune Response

by Zacks Equity Research

Glaxo (GSK) and its partner Medicago's adjuvant COVID-19 vaccine candidate induces robust neutralizing antibody and cellular immune responses in mid-stage study participants.

Novavax's (NVAX) Q1 Loss Widens, Revenues Beat, Shares Down

by Zacks Equity Research

Novavax (NVAX) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. Shares fall in after-hours trading.

Theravance (TBPH) Q1 Earnings Lag Estimates, Pipeline on Track

by Zacks Equity Research

Theravance's (TBPH) loss narrows in the first quarter of 2021 while revenues decline year over year.

The Zacks Analyst Blog Highlights: Eli Lilly, Merck, GlaxoSmithKline, Novartis and Johnson & Johnson

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Eli Lilly, Merck, GlaxoSmithKline, Novartis and Johnson & Johnson

Kinjel Shah headshot

Pharma Stock Roundup: Big Drugmakers' Q1 Earnings, Resumption of JNJ US COVID-19 Jabs

by Kinjel Shah

Several large drugmakers announce Q1 earnings. Many miss estimates for both earnings and sales. J&J (JNJ) resumes COVID-19 vaccination in the United States.

Gilead (GILD) Beats on Q1 Earnings, HIV Sales Decline

by Zacks Equity Research

Gilead (GILD) reports mixed results for the first quarter as the ongoing pandemic adversely impacted core HIV segment sales.

Seagen (SGEN) Q1 Loss Wider Than Expected, Revenues Rise Y/Y

by Zacks Equity Research

Seagen (SGEN) lags estimates for earnings and revenues in the first quarter of 2021. Shares lose ground in after-hour trading.

Glaxo's (GSK) Q1 Earnings In Line, Sales Hit by COVID-19

by Zacks Equity Research

Glaxo's (GSK) revenues get hurt by disruption related to COVID-19 pandemic. However, robust growth in respiratory, immuno-inflammation and cancer drugs partially offset the decline.

Sanofi (SNY) Q1 Earnings & Sales Beat, Keeps 2021 EPS View

by Zacks Equity Research

Sanofi's (SNY) Q1 earnings and sales beat estimates. Dupixent drives sales growth in the quarter.